BenQ Medical Technology 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BenQ Medical Technology.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Medical Equipment 수익 성장	23.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

There's Been No Shortage Of Growth Recently For BenQ Medical Technology's (GTSM:4116) Returns On Capital

Apr 07

Estimating The Fair Value Of BenQ Medical Technology Corporation (GTSM:4116)

Mar 23

BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 49% On Their Shares

Mar 08

Does BenQ Medical Technology Corporation (GTSM:4116) Have A Place In Your Dividend Stock Portfolio?

Feb 17

BenQ Medical Technology (GTSM:4116) Seems To Use Debt Quite Sensibly

Jan 29

BenQ Medical Technology Corporation's (GTSM:4116) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?

Jan 11

The Returns At BenQ Medical Technology (GTSM:4116) Provide Us With Signs Of What's To Come

Dec 24

BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 72% On Their Shares

Dec 07

Should You Buy BenQ Medical Technology Corporation (GTSM:4116) For Its 4.4% Dividend?

Nov 17

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 BenQ Medical Technology 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

TPEX:4116 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (TWD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	4,597	126	264	407	N/A
3/31/2024	4,546	115	315	422	N/A
12/31/2023	4,543	115	303	442	N/A
9/30/2023	4,506	101	194	353	N/A
6/30/2023	4,467	98	300	457	N/A
3/31/2023	4,816	115	354	493	N/A
12/31/2022	4,377	180	403	483	N/A
9/30/2022	3,624	169	307	372	N/A
6/30/2022	2,885	143	186	214	N/A
3/31/2022	1,748	112	154	178	N/A
12/31/2021	1,465	29	88	121	N/A
9/30/2021	1,455	48	117	164	N/A
6/30/2021	1,445	54	142	196	N/A
3/31/2021	1,432	59	100	155	N/A
12/31/2020	1,401	62	109	151	N/A
9/30/2020	1,349	54	32	63	N/A
6/30/2020	1,331	59	58	83	N/A
3/31/2020	1,348	63	111	131	N/A
12/31/2019	1,380	75	148	169	N/A
9/30/2019	1,370	80	205	238	N/A
6/30/2019	1,331	77	158	191	N/A
3/31/2019	1,307	82	126	159	N/A
12/31/2018	1,233	67	88	126	N/A
9/30/2018	1,154	55	-1	28	N/A
6/30/2018	1,144	49	-24	46	N/A
3/31/2018	1,085	45	N/A	63	N/A
12/31/2017	1,037	47	N/A	73	N/A
9/30/2017	985	44	N/A	116	N/A
6/30/2017	901	42	N/A	99	N/A
3/31/2017	871	43	N/A	58	N/A
12/31/2016	876	46	N/A	71	N/A
9/30/2016	922	23	N/A	87	N/A
6/30/2016	913	22	N/A	63	N/A
3/31/2016	925	115	N/A	59	N/A
12/31/2015	938	118	N/A	86	N/A
9/30/2015	951	149	N/A	50	N/A
6/30/2015	1,022	167	N/A	95	N/A
3/31/2015	1,046	82	N/A	126	N/A
12/31/2014	1,015	78	N/A	104	N/A
9/30/2014	945	69	N/A	131	N/A
6/30/2014	869	57	N/A	116	N/A
3/31/2014	806	43	N/A	115	N/A
12/31/2013	806	42	N/A	114	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if 4116's forecast earnings growth is above the savings rate (1%).

수익 vs 시장: Insufficient data to determine if 4116's earnings are forecast to grow faster than the TW market

고성장 수익: Insufficient data to determine if 4116's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if 4116's revenue is forecast to grow faster than the TW market.

고성장 수익: Insufficient data to determine if 4116's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if 4116's Return on Equity is forecast to be high in 3 years time

BenQ Medical Technology 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.66 (vs NT$0.40 in 2Q 2023)

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Upcoming dividend of NT$2.00 per share

First quarter 2024 earnings released: EPS: NT$0.51 (vs NT$0.51 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$2.57 (vs NT$4.04 in FY 2022)

BenQ Medical Technology Corporation, Annual General Meeting, Jun 07, 2024

New minor risk - Earnings quality

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.40 (vs NT$0.78 in 2Q 2022)

New minor risk - Profit margin trend

Upcoming dividend of NT$2.10 per share at 3.5% yield

No independent directors

Third quarter 2022 earnings released: EPS: NT$0.78 (vs NT$0.19 in 3Q 2021)

Now 23% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: NT$0.78 (vs NT$0.075 in 2Q 2021)

Investor sentiment deteriorated over the past week

Upcoming dividend of NT$0.50 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: NT$1.97 (vs NT$0.11 in 1Q 2021)

No independent directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.19 (vs NT$0.32 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.08 (vs NT$0.19 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.18 in 1Q 2020)

There's Been No Shortage Of Growth Recently For BenQ Medical Technology's (GTSM:4116) Returns On Capital

Estimating The Fair Value Of BenQ Medical Technology Corporation (GTSM:4116)

BenQ Medical Technology Corporation, Annual General Meeting, Jun 10, 2021

Full year 2020 earnings released: EPS NT$1.39 (vs NT$1.69 in FY 2019)

BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 49% On Their Shares

Does BenQ Medical Technology Corporation (GTSM:4116) Have A Place In Your Dividend Stock Portfolio?

BenQ Medical Technology (GTSM:4116) Seems To Use Debt Quite Sensibly

BenQ Medical Technology Corporation's (GTSM:4116) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?

The Returns At BenQ Medical Technology (GTSM:4116) Provide Us With Signs Of What's To Come

New 90-day high: NT$34.95

BenQ Medical Technology's (GTSM:4116) Shareholders Are Down 72% On Their Shares

New 90-day high: NT$32.65

Should You Buy BenQ Medical Technology Corporation (GTSM:4116) For Its 4.4% Dividend?

Third quarter 2020 earnings released: EPS NT$0.32

New 90-day low: NT$30.00

New 90-day low: NT$30.40

First half earnings released

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견